Companies › UCB Biopharma SRL
9 active drug programs in 30 registered trials: 14 Phase 3, 8 Phase 2, 6 Phase 1, 2 Phase 4; Neurology, Immunology, Other, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rozanolixizumab IgG receptor FcRn large subunit p51 inhibitor | FCGRT | Phase 4 | Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD); Generalized Myasthenia Gravis; Ocular Myasthenia Gravis | May 2027 |
| Bimekizumab Interleukin 17A inhibitor; Interleukin-17F inhibitor | IL17A, IL17F | Phase 3 | Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis … | Dec 2026 |
| Alprazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Stereotypical Prolonged Seizures; Ophthalmology; Opioid Abuse; Drug Interactions | Mar 2027 |
| dapirolizumab pegol CD40 ligand inhibitor | CD40LG | Phase 3 | Systemic Lupus Erythematosus | May 2028 |
| Brivaracetam Synaptic vesicle glycoprotein 2A modulator | SV2A | Phase 3 | Childhood Absence Epilepsy; Epilepsy | Nov 2029 |
| Zilucoplan Complement C5 inhibitor | C5 | Phase 2 | Generalized Myasthenia Gravis; Healthy Participants; Generalized Myasthenia Gravis (gMG); Amyotrophic Lateral Sclerosis | Mar 2027 |
| Galvokimig (UCB9741) Neutrophil elastase inhibitor | – | Phase 2 | Atopic Dermatitis; Non-cystic Fibrosis Bronchiectasis; Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | May 2027 |
| UCB5285 | – | Phase 1 | Healthy Participants | Dec 2026 |
| Bepranemab (UCB0107) Microtubule-associated protein tau inhibitor | MAPT | Phase 1 | Progressive Supranuclear Palsy | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06149559 | Rozanolixizumab | Phase 2 | Generalized Myasthenia Gravis | Neurology | Oct 2026 |
| NCT07286682 | UCB5285 | Phase 1 | Healthy Participants | Other | Dec 2026 |
| NCT05006079 | Alprazolam | Phase 2 | Opioid Abuse | Psychiatry | Dec 2026 |
| NCT06921850 | Bimekizumab | Phase 3 | Hidradenitis Suppurativa | Immunology | Dec 2026 |
| NCT06506916 | Bimekizumab | Phase 3 | Moderate to Severe Plaque Psoriasis | Immunology | Mar 2027 |
| NCT06961747 | Zilucoplan | Phase 1 | Healthy Participants | Other | Mar 2027 |
| NCT05077904 | Alprazolam | Phase 3 | Stereotypical Prolonged Seizures | Neurology | Mar 2027 |
| NCT05063162 | Rozanolixizumab | Phase 3 | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) | Neurology | May 2027 |
| NCT06055959 | Zilucoplan | Phase 2 | Generalized Myasthenia Gravis | Neurology | May 2027 |
| NCT07277660 | Galvokimig (UCB9741) | Phase 2 | Atopic Dermatitis | Immunology | May 2027 |
| NCT04297683 | Zilucoplan | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Jul 2027 |
| NCT06540144 | Rozanolixizumab | Phase 3 | Generalized Myasthenia Gravis | Neurology | Oct 2027 |
| NCT07246564 | Rozanolixizumab | Phase 4 | Myasthenia Gravis | Neurology | Oct 2027 |
| NCT07215949 | Zilucoplan | Phase 3 | Generalized Myasthenia Gravis (gMG) | Neurology | Dec 2027 |
| NCT04658199 | Bepranemab (UCB0107) | Phase 1 | Progressive Supranuclear Palsy | Neurology | Dec 2027 |
| NCT07219420 | Bimekizumab | Phase 3 | Palmoplantar Pustulosis | Immunology | Dec 2027 |
| NCT06874452 | Alprazolam | Phase 4 | Ophthalmology | Ophthalmology | Dec 2027 |
| NCT06888193 | Bimekizumab | Phase 1 | Moderate to Severe Plaque Psoriasis | Immunology | Dec 2027 |
| NCT06668181 | Bimekizumab | Phase 3 | Enthesitis-related Arthritis | Immunology | Apr 2028 |
| NCT07290036 | Bimekizumab | Phase 1 | Psoriatic Arthritis | Immunology | May 2028 |
| NCT06617325 | dapirolizumab pegol | Phase 3 | Systemic Lupus Erythematosus | Immunology | May 2028 |
| NCT06742333 | Bimekizumab | Phase 2 | Psoriasis | Immunology | Jul 2028 |
| NCT06425549 | Bimekizumab | Phase 3 | Moderate to Severe Plaque Psoriasis | Immunology | Aug 2028 |
| NCT07463521 | Rozanolixizumab | Phase 3 | Ocular Myasthenia Gravis | Neurology | Dec 2028 |
| NCT06757140 | Alprazolam | Phase 1 | Drug Interactions | Other | Jan 2029 |
| NCT07720375 | Galvokimig (UCB9741) | Phase 2 | Non-cystic Fibrosis Bronchiectasis | Respiratory | Feb 2029 |
| NCT07725939 | Galvokimig (UCB9741) | Phase 2 | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | Respiratory | Jun 2029 |
| NCT06315322 | Brivaracetam | Phase 3 | Childhood Absence Epilepsy | Neurology | Nov 2029 |
| NCT04715646 | Brivaracetam | Phase 3 | Epilepsy | Neurology | Jul 2030 |
| NCT07465289 | Rozanolixizumab | Phase 3 | Ocular Myasthenia Gravis | Neurology | Mar 2031 |
CD40LG (1) FCGRT (1) GABRA1 (1) GABRB2 (1) GABRG2 (1) GABRB3 (1) GABRA4 (1) IL17A (1) IL17F (1) C5 (1) SV2A (1) MAPT (1)
Ono Pharmaceutical Lipocine Haisco Pharmaceutical Group SK Life Science Acacia Pharma Sedana Medical AbbVie Eledon Pharmaceuticals Amgen Johnson & Johnson (Janssen)
Biogen H. Lundbeck SK Life Science Teva Branded Pharmaceutical Products R&D Pharming Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.